Key takeaways
Nucala (mepolizumab) and Xolair (omalizumab) are both injectable medications used to treat asthma and nasal polyps, but they belong to different medication classes. Nucala is an interleukin antagonist that blocks interleukin-5 (IL-5) to reduce inflammation, while Xolair is an immunoglobulin E (IgE) monoclonal antibody that targets IgE to reduce the immune system's allergic response. Nucala is also approved for eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES), whereas Xolair is used for chronic urticaria and to lower the risk of severe food allergy reactions. Nucala is typically given once a month, while Xolair is administered every 2 or 4 weeks, with dosing based on factors like body weight and IgE levels. Both medications can be self-administered at home with proper training. Common side effects of both medications include headache and injection-site reactions.
